News

The study is designed to assess the effectiveness of a panel of Neogenix monoclonal antibodies as diagnostic markers for colorectal and pancreatic cancer. The diagnostic properties of these

The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under

The AnalyST implantable cardioverter defibrillator (ICD) with ST Monitoring is said to be the industry’s first device to continuously monitor specific changes in the heart’s electrical system which

The company’s decision to submit a clinical trial application (CTA) follows a board review of progress with Atu027 and, in particular, consideration of recent discussions with BfArM, the

The European approval provides a significantly broader indication for peginterferon alfa-2a and establishes a new standard of care for treatment-experienced patients with the most difficult-to-treat virus, the company

The first study 030 compared the pulmonary safety of meal-time inhalation of Afresa versus usual care in over 2000 patients with type 1 and type 2 diabetes. The

According to the company, approximately 19 end stage blood cancer patients were treated with no cases of grade III/IV acute graft versus host disease (GVHD) occurring within the

The program enrolled 282 patients who underwent cataract surgery in two US multi-center, randomized, double-masked, parallel-group, vehicle-controlled studies to evaluate Xibrom (0.09% bromfenac sodium ophthalmic solution) dosed once

The prior approved label claim allowed Intercept treatment only within eight hours of blood collection. This new extended treatment window applies to plasma from single donor apheresis and